- Home
- BDRX vs XRTX Comparison
BDRX vs XRTX Comparison
Compare BDRX & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- XRTX
- Stock Information
- Founded
- BDRX 2000
- XRTX 2011
- Country
- BDRX United Kingdom
- XRTX Canada
- Employees
- BDRX N/A
- XRTX N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- XRTX Pharmaceuticals and Biotechnology
- Sector
- BDRX Health Care
- XRTX Health Care
- Exchange
- BDRX Nasdaq
- XRTX Nasdaq
- Market Cap
- BDRX 3.6M
- XRTX 4.2M
- IPO Year
- BDRX N/A
- XRTX N/A
- Fundamental
- Price
- BDRX $1.15
- XRTX $0.92
- Analyst Decision
- BDRX
- XRTX
- Analyst Count
- BDRX 0
- XRTX 0
- Target Price
- BDRX N/A
- XRTX N/A
- AVG Volume (30 Days)
- BDRX 3.6M
- XRTX 34.6K
- Earning Date
- BDRX 04-11-2025
- XRTX 05-16-2025
- Dividend Yield
- BDRX N/A
- XRTX N/A
- EPS Growth
- BDRX N/A
- XRTX N/A
- EPS
- BDRX N/A
- XRTX N/A
- Revenue
- BDRX N/A
- XRTX N/A
- Revenue This Year
- BDRX N/A
- XRTX N/A
- Revenue Next Year
- BDRX N/A
- XRTX N/A
- P/E Ratio
- BDRX N/A
- XRTX N/A
- Revenue Growth
- BDRX N/A
- XRTX N/A
- 52 Week Low
- BDRX $1.01
- XRTX $0.80
- 52 Week High
- BDRX $41.50
- XRTX $2.98
- Technical
- Relative Strength Index (RSI)
- BDRX 39.66
- XRTX 43.86
- Support Level
- BDRX $1.01
- XRTX $0.88
- Resistance Level
- BDRX $1.26
- XRTX $0.97
- Average True Range (ATR)
- BDRX 0.12
- XRTX 0.06
- MACD
- BDRX 0.01
- XRTX -0.01
- Stochastic Oscillator
- BDRX 15.22
- XRTX 18.85
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.